In an insightful interview with VaccineNation, Adam French, the Vice President of Operations at hVIVO, unveiled the launch of hLab, a state-of-the-art virology and immunology lab service designed to enhance vaccine development. hLab, backed by decades of scientific expertise, promises to accelerate the process of vaccine development through its advanced assays and capabilities for global trials. French shared how the lab’s cutting-edge facilities would play a pivotal role in driving forward vaccine innovation, particularly highlighting its latest collaboration on a flu trial.
The introduction of hLab signifies a major milestone for hVIVO, marking a significant expansion of its operations in the field of virology and immunology. With its highly sophisticated lab service, hLab is poised to support faster, more efficient vaccine trials, ultimately contributing to global health advancements. By offering world-class services, including global trial coordination and the application of advanced testing techniques, hLab aims to redefine the landscape of vaccine development.
French elaborated on the potential of hLab to streamline vaccine research, citing the lab’s advanced technologies and unparalleled expertise. The collaboration with global teams on the latest flu trial is just one example of how hLab is already pushing the boundaries of what is possible in immunology. Through these initiatives, hVIVO is committed to driving innovation and making a substantial impact in the fight against infectious diseases.
The launch of hLab represents a transformative step forward in the field of vaccine development, reinforcing hVIVO’s commitment to advancing global health through innovation and expertise.
hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.
